BioCentury This Week Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what the latest shakeup at the regulatory agency says about what’s next for FDA.
The analysts also assess two leading European pharmas: obesity and diabetes company Novo Nordisk, which named a new CEO last week while cutting its 2025 forecast, and Bayer, which is gearing up for launches and is revamping its pipeline to restart growth. Finally, they discuss the promising clinical data that’s reviving interest in masking technologies that conditionally activate biologics.
View full story: https://www.biocentury.com/article/656649
#FDA #CBER #NovoNordisk #ObesityDrugs #Bayer
01:05 - Prasad's Ouster
14:59 - Novo's New CEO
21:14 - Bayer's Growth Strategy
26:05 - Masked Biologics
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.